Last updated: March 1, 2026
What is the Indication and Composition of NDC 80803-0153?
NDC 80803-0153 is a drug marketed as Trelagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes mellitus. It is administered once weekly, offering a convenient dosing schedule. The current formulation is a 50 mg tablet.
Market Dynamics for DPP-4 Inhibitors
DPP-4 inhibitors are part of a broader class of oral hypoglycemics, including sitagliptin, saxagliptin, linagliptin, and alogliptin. These drugs are among the top-selling antidiabetics globally, driven by the rising prevalence of type 2 diabetes.
Market size
- The global diabetes drug market was valued at approximately $57.2 billion in 2021 (Grand View Research, 2022).
- DPP-4 inhibitors account for around 35%–40% of this market, translating to roughly $20–$23 billion in 2021.
Key competitors
| Drug Name |
Dosage |
Approval Year |
Mode of Action |
Dosing Frequency |
Market Share (2022) |
| Sitagliptin |
25–100 mg |
2006 |
DPP-4 inhibition |
Daily |
55% |
| Saxagliptin |
2.5–5 mg |
2009 |
DPP-4 inhibition |
Daily |
12% |
| Linagliptin |
5 mg |
2011 |
DPP-4 inhibition |
Daily |
10% |
| Alogliptin |
25 mg |
2013 |
DPP-4 inhibition |
Daily |
8% |
| Trelagliptin |
50 mg |
2015 |
DPP-4 inhibition |
Weekly |
<1% |
Market penetration of Trelagliptin
- Launched in Japan in 2015; limited to that market.
- No significant penetration in global markets due to limited approval, patent exclusivity, and competition with daily formulations.
Patent Status and Regulatory Environment
- Trelagliptin's patent expired in Japan in 2020; no current patent protection globally.
- Limited regulatory approval outside Japan restricts market expansion.
- Generic competition for daily DPP-4 inhibitors is widespread and well-established.
Pricing Trends
Current Price Points
| Product Name |
Approximate Wholesale Price (per 50 mg tablet) |
Market (Geography) |
| Trelagliptin (Japan) |
$3.00–$5.00 |
Japan |
| Sitagliptin |
$0.50–$1.00 |
Global (generic) |
| Saxagliptin |
$0.60–$1.20 |
Global (generic) |
| Linagliptin |
$1.00–$2.00 |
Global (generic) |
Price Drivers
- DPP-4 inhibitors have experienced pricing erosion due to generic entry.
- The convenience of once-weekly dosing has limited impact on price premiums, given the prevalence of daily formulations.
Future Market and Price Projections
Market Estimates (2023–2028)
- As a pharmaceutical with limited market expansion, Trelagliptin is unlikely to see significant sales growth outside Japan.
- Estimated annual global sales: under $10 million, primarily driven by the Japanese market.
Price Projections
- Wholesale prices are expected to decline by 10–15% annually due to market saturation and generic competition.
- In Japan, prices could stabilize around $2–$4 per tablet, reflecting market dynamics and pricing regulations.
Potential Drivers for Pricing Changes
- Introduction of a branded, once-weekly DPP-4 inhibitor in global markets.
- New formulation advancements or combination therapies.
- Regulatory approvals in additional countries.
Risks and Opportunities
Risks
- Patent expiration diminishes exclusivity.
- Competition from well-established daily DPP-4 inhibitors.
- Pricing pressures from generic manufacturers.
Opportunities
- Market exclusivity in countries with delayed generic entry.
- Potential for combination formats with other antidiabetics.
- Expansion in markets where once-weekly formulations are adopted.
Conclusion
NDC 80803-0153 (Trelagliptin) has limited market share outside Japan and no current significant price advantage over daily DPP-4 inhibitors. Market growth prospects remain constrained by patent expiration, competition, and regulatory limitations. Prices are expected to decline steadily in the next five years, aligning with industry trends in the face of generics.
Key Takeaways
- Trelagliptin is a weekly DPP-4 inhibitor with minimal market presence outside Japan.
- The drug faces intense price competition from earlier-generation daily DPP-4 inhibitors, which dominate the market.
- Future sales opportunities are limited unless new formulations or markets are developed.
- Prices are projected to decrease annually by roughly 10–15%, influenced by generic competition and pricing strategies.
- Market expansion depends on regulatory approvals and potential benefit over existing therapies.
FAQs
Q1: Can Trelagliptin expand beyond the Japanese market?
Yes, but expansion depends on regulatory approval in new countries, which has not yet occurred.
Q2: Will the price of Trelagliptin increase with patent expiration?
No, patent expiration typically leads to price reductions due to generic competition.
Q3: How does the convenience of weekly dosing influence pricing?
Despite convenience, pricing remains aligned with daily formulations because of market competition and price sensitivity.
Q4: Are there any pending regulatory or patent protections for Trelagliptin?
No, patents have expired in key markets, and regulatory approvals are limited.
Q5: What factors could raise Trelagliptin’s market value?
Introducing enhanced formulations, combination therapies, or obtaining approvals in additional markets could improve its market position.
References
- Grand View Research. (2022). Diabetes drugs market size, share & trends analysis report.
- U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
- Smith, J. (2021). Analysis of DPP-4 inhibitor market dynamics. Journal of Pharmaceutical Marketing.
